incidence
The crude incidence of ovarian cancer in the European Union is 18, the mortality is 12/100 000 women/year. The median age at diagnosis is 63 years. The incidence increases with age and peaks in the eighth decade. Between the ages of 70 and 74 years the age-specific incidence is 57/100 000 women/year.
diagnosis
The definitive diagnosis of epithelial ovarian cancer requires a surgical specimen. Pathological diagnosis should be made according to the World Health Organization classification. Established subtypes are: serous, mucinous, endometrioid, clear cell, Brenner, mixed and undifferentiated carcinomas.
staging and risk assessment
Surgical staging requires a median laparotomy with a thorough examination of the abdominal cavity according to Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) classification guidelines. If disease appears confined to the ovary, biopsy of the diaphragmatic peritoneum, paracolic gutters, pelvic peritoneum and an infracolic omentectomy, and sampling or dissection of para-aortic and pelvic nodes are required in addition to peritoneal washings.
Surgery should be performed by an appropriately trained gynaecologic oncologist with experience in the management of ovarian cancer [III, B] .
Staging is described using the FIGO and American Joint Committee on Cancer (AJCC) classification and FIGO as in the Before surgery and/or chemotherapy, patients should have an abdomino-pelvic CT scan, chest X-ray, serum CA125, complete blood count and differential, and biochemistry for renal and hepatic function.
treatment plan
The selection of the type of surgery and postoperative chemotherapy depends upon the stage and other clinicopathological prognostic factors.
early stage disease, FIGO I and IIa
Surgery should involve total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, random peritoneal biopsies including the paracolic gutters and at least pelvic/ para-aortic lymph node sampling performed as described above. In younger patients wanting to conserve fertility with localized, unilateral tumors (stage I) and favorable histology, unilateral salpingo-oophorectomy may not be associated with a high risk of recurrence. Wedge biopsy of the contralateral ovary should be performed, if the contralateral ovary is not normal on inspection. FIGO stage I tumors with dense adhesions to other pelvic structures should be 'upstaged' and treated as FIGO II tumors, as the relapse rate appears to be similar.
FIGO There is no evidence for a survival benefit of 'second-look' surgery following completion of chemotherapy in patients whose disease appears to be in complete remission. Such procedures should only be undertaken as part of a clinical trial. Likewise, the value of secondary tumor reduction at the time of second-look laparotomy is not clear.
Intraperitoneal chemotherapy should be considered an option for selected patients in centers where the expertise exists.
Neoadjuvant chemotherapy for patients considered initially not optimally resectable for either tumor or patient-related factors is a viable alternative strategy; however, available data suggest that the survival outcome may be inferior to successful primary surgery followed by chemotherapy. Young patients with good performance status, pleural effusion as the only site of disease outside the abdominal cavity, small volume metastases and no major organ dysfunction should be considered for surgery as outlined above.
If surgery is not planned, the diagnosis should be confirmed by biopsy and chemotherapy administered as recommended above for FIGO stage IIb-IIIc disease.
response evaluation CA125 levels during chemotherapy can accurately correlate with tumor response and with survival [III, A]. Serum CA125 should be measured at regular intervals during chemotherapy (e.g. before each cycle).
For patients with abnormal CT scan at baseline, this should be repeated after cycle 6 unless there is evidence (e.g. CA125 levels not falling) of non-responding disease; in this case an earlier CT scan would be indicated. Patients with normal CT scans at baseline do not need further CT scans, provided there is no clinical or biochemical indication of disease progression. An interim CT scan after three cycles of chemotherapy should be considered for a patient who is negative for serum CA125, or for whom interval debulking surgery is being considered.
Current data do not support a recommendation of maintenance/consolidation treatment beyond six cycles; however, the data for 12 months of paclitaxel maintenance should be discussed with patients with respect to the potential improvement observed in PFS [II, C] 
